Gastroenterology

Gastroenterology

Volume 116, Issue 6, June 1999, Pages 1413-1419
Gastroenterology

Liver, Pancreas, and Biliary Tract
Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity,☆☆

Presented in part at Digestive Diseases Week, May 1998, New Orleans, Louisiana.
https://doi.org/10.1016/S0016-5085(99)70506-8Get rights and content

Abstract

Background & Aims: The spectrum of nonalcoholic fatty liver disease ranges from fatty liver alone to nonalcoholic steatohepatitis. Most previous studies have short follow-up and have not carefully delineated different histological types when determining clinical outcomes. The aim of this study was to compare clinical characteristics and outcomes of patients with different types of nonalcoholic fatty liver. Methods: All liver biopsy specimens from 1979 to 1987 with fat accumulation were assessed for inflammation, ballooning degeneration, Mallory hyaline, and fibrosis. Biopsy specimens were also assessed for histological iron and hepatitis C RNA. Outcomes were cirrhosis, mortality, and liver-related mortality. Results: Of 772 liver biopsy specimens, complete data were available in 132 patients. Fatty liver (type 1) did not differ from the other three types combined with respect to gender, race, age, or obesity. Cirrhosis was more common in the other types combined (22%) than fatty liver alone (4%; P ≤ 0.001). Overall mortality, histological iron, and hepatitis C did not differ between groups. Most of the liver-related deaths were in type 4. Conclusions: The outcome of cirrhosis and liver-related death is not uniform across the spectrum of nonalcoholic fatty liver. These poor outcomes are more frequent in patients in whom biopsies show ballooning degeneration and Mallory hyaline or fibrosis.

GASTROENTEROLOGY 1999;116:1413-1419

Section snippets

Patient population

All liver biopsy specimens obtained 1979 through 1987 with a histological diagnosis of fatty liver (minimum inclusion criteria) were identified through a computerized pathology registry at the Cleveland Clinic. This time period would allow up to 18 years of follow-up for survival analysis and determination of disease progression. Exclusionary criteria included the following: (1) daily alcohol intake >30 g in men or >20 g in women; (2) use of amiodarone, corticosteroids, tamoxifen, methotrexate,

Results

We identified 772 liver biopsy specimens with fatty liver from our computerized pathology registry. After application of exclusion criteria, 157 patients remained, 132 of whom had complete clinical and pathological data. Reasons for liver biopsy were as follows: incidental (i.e., biopsy performed during cholecystectomy or consideration for methotrexate in psoriasis, but methotrexate was never given), 43%; abnormal liver test results, 29%; suspicion of liver disease or cirrhosis, 16%; and

Discussion

This study, with the largest number of patients and longest follow-up of its kind, used established and reliable histological criteria to evaluate outcomes stratified for the different forms of nonalcoholic fatty liver. NAFLD patients were initially separated into four specific histological diagnoses: simple fatty liver (type 1), steatohepatitis (type 2), steatonecrosis (type 3), and steatonecrosis plus either Mallory hyaline or fibrosis (type 4). The demographic and clinical parameters of age,

Acknowledgements

The authors thank Stephen Day, Ph.D., of ViroMED Laboratories, Inc., and Belinda Yen-Lieberman, Ph.D., of the Department of Microbiology, Cleveland Clinic, for their assistance with tissue hepatitis C virus RNA by polymerase chain reaction.

References (30)

  • AM Di Bisceglie et al.

    Measurement of iron status in patients with chronic hepatitis

    Gastroenterology

    (1992)
  • JE Lavine

    Treatment of obesity-induced steatohepatitis with vitamin E (abstr)

    Gastroenterology

    (1998)
  • J Laurin et al.

    Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

    Hepatology

    (1996)
  • F Schaffner et al.

    Nonalcoholic fatty liver disease

    Prog Liver Dis

    (1986)
  • ZM Younossi et al.

    Non-alcoholic fatty liver disease: assessment of variability in pathologic interpretations

    Mod Pathol

    (1998)
  • Cited by (0)

    Address requests for reprints to: Zobair M. Younossi, M.D., M.P.H., Department of Gastroenterology/S40, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195. e-mail: [email protected]; fax: (216) 444-9416.

    ☆☆

    Supported in part by a grant from the American College of Gastroenterology.

    View full text